Soleus Capital Management L.P. Sells 164,300 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Soleus Capital Management L.P. trimmed its position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 68.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 75,405 shares of the company's stock after selling 164,300 shares during the quarter. Soleus Capital Management L.P. owned approximately 0.15% of Enliven Therapeutics worth $1,697,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Stempoint Capital LP acquired a new stake in Enliven Therapeutics in the fourth quarter valued at approximately $2,176,000. Polar Capital Holdings Plc raised its holdings in shares of Enliven Therapeutics by 267.6% during the 4th quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company's stock valued at $53,768,000 after purchasing an additional 1,739,668 shares in the last quarter. ProShare Advisors LLC lifted its stake in shares of Enliven Therapeutics by 29.5% in the 4th quarter. ProShare Advisors LLC now owns 12,229 shares of the company's stock valued at $275,000 after purchasing an additional 2,788 shares during the last quarter. Patient Square Capital LP lifted its stake in shares of Enliven Therapeutics by 147.4% in the 4th quarter. Patient Square Capital LP now owns 224,038 shares of the company's stock valued at $5,041,000 after purchasing an additional 133,466 shares during the last quarter. Finally, Millennium Management LLC boosted its holdings in Enliven Therapeutics by 108.6% in the fourth quarter. Millennium Management LLC now owns 50,804 shares of the company's stock worth $1,143,000 after purchasing an additional 26,449 shares in the last quarter. Institutional investors own 95.08% of the company's stock.

Enliven Therapeutics Stock Performance

Enliven Therapeutics stock traded down $0.16 during trading hours on Thursday, hitting $16.77. 105,778 shares of the stock were exchanged, compared to its average volume of 259,762. The stock has a market capitalization of $822.89 million, a P/E ratio of -8.83 and a beta of 1.07. The business's 50-day moving average is $18.62 and its two-hundred day moving average is $21.52. Enliven Therapeutics, Inc. has a 12 month low of $13.30 and a 12 month high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). On average, equities analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on ELVN shares. HC Wainwright boosted their target price on Enliven Therapeutics from $39.00 to $40.00 and gave the stock a "buy" rating in a report on Thursday, May 15th. Jones Trading reduced their price objective on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a research note on Friday, May 16th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Enliven Therapeutics presently has an average rating of "Buy" and a consensus price target of $37.25.

Insider Activity

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 3,250 shares of the stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $20.41, for a total value of $66,332.50. Following the transaction, the chief financial officer now owns 13,000 shares of the company's stock, valued at approximately $265,330. This represents a 20.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Samuel Kintz sold 5,000 shares of the business's stock in a transaction dated Monday, May 19th. The stock was sold at an average price of $16.49, for a total value of $82,450.00. Following the transaction, the chief executive officer now owns 972,892 shares of the company's stock, valued at $16,042,989.08. The trade was a 0.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 86,111 shares of company stock valued at $1,657,145. Company insiders own 29.20% of the company's stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.